A response to the opioid overdose epidemic: Naloxone nasal spray

Drug Delivery and Translational Research

Volumn 3, Issue 1, 2013, Pages 63-74

  Wermeling, Daniel P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antidote; Intranasal; Naloxone; Opioid; Overdose

Indexed keywords

BUTORPHANOL; HYDROMORPHONE; NALOXONE; NALTREXONE; OPIATE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG FORMULATION; DRUG OVERDOSE; EPIDEMIC; HEPATITIS VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NEEDLESTICK INJURY; NONHUMAN; NOSE; PHARMACEUTICS; PRIORITY JOURNAL; PUBLIC HEALTH; RAT; REVIEW;

EID: 84875530276     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0092-0     Document Type: Review

References (64)

1. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 2011. NCHS data brief, no 81. Hyattsville, MD: National Center for Health Statistics, 1980-2008.
2. Centers for Disease Control and Prevention, National Center for Health Statistics. Deaths: preliminary data for 2009. Natl Vital Stat Rep. 2011; 59: 17-20.
3. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. November 1, 2011; 60: 1-6.
4. Centers of Disease Control and Prevention, Morbidity and Mortality Weekly Report. CDC grand rounds: prescription drug overdoses-a U. S. epidemic. January 13, 2012; 61(1): 10-4.
5. Coben JH, Davis SM, Furbee PM, et al. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med. 2010; 38(5): 517-24.
6. Dawn Report-Emergency department visits involving nonmedical use of selected pharmaceuticals. Issue 23, 2006 R. http://DAWNinfo. samsha. gov. Accessed October 2009.
7. Milloy MJ, Wood E, Reading C, Kane D, Montaner J, Kerr T. Elevated overdose mortality rates among first nations individuals in a Canadian setting: a population-based analysis. Addiction. 2010; 105: 1962-70.
8. Strang J, Manning V, Mayet S, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008; 103: 1648-57.
9. Preti A, Miotto P, De Coppi M. Deaths by unintentional illicit drug overdose in Italy, 1984-2000. Drug Alcohol Depend. 2002; 66: 275-82.
10. Coffin P. Overdose: a major cause of preventable death in central and eastern Europe and central Asia: recommendations and overview of the situation in Latvia, Kyrgyzstan, Romania, Russia and Tajikistan. Eurasian Harm Reduction Network (EHRN), Vilnius, August 2008.
11. Quan VM, Minh NL, Ha TV, et al. Mortality and HIV transmission among male Vietnamese injection drug users. Addiction. 2011; 106: 583-9.
12. Hall WD, Degenhardt LJ, Lynskey MT. Opioid overdose mortality in Australia, 1964-1997: birth-cohort trends. Med J Aust. 1999; 171: 34-7.
13. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009; 99: 788-91.
14. AHFS Drug Information Naloxone Hydrochloride monograph. American Society of Health System Pharmacists. 2009: 2251-54.
15. International Medication Systems, Limited. Naloxone hydrochloride injection prescribing information 2001.
16. Hospira, Inc. Naloxone hydrochloride injection prescribing information 2006. Available from: http://dailymed. nlm. nih. gov/dailymed/archives/fdaDrugInfo. cfm?archiveid=2668.
17. Sporer KA, Kral AH. Out of hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med. 1996; 3(7): 660-7.
18. Belz D, Lieb J, Rea T, Eisenberg MS. Naloxone use in a tiered response emergency medical services system. Prehospital Emergency Care. 2006; 10(4): 468-71.
19. Barton ED, Ramos J, Colwell C, Benson J, Baily J, Dunn W. Intranasal administration of naloxone by paramedics. Prehospital Emergency Care. 2002; 6(1): 54-8.
20. Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the pre-hospital setting. J Emerg Med. 2005; 29(3): 265-71.
21. Kerr D, Dietze P, Kelly A. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction. 2008; 103: 379-86.
22. Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomized trial of intranasal versus intramuscular naloxone in prehospital treatment of suspected opioid overdose. MJA. 2005; 182(1): 24-7.
23. Robertson GW, Stroh G, Shalit M. Intranasal vs intravenous naloxone for prehospital narcotic overdose. Acad Emerg Med. 2005; 12((5) Suppl 1): 166.
24. Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. PreHosp Emerg Care. 2009; 13(4): 512-5.
25. Merlin MA, Saybolt M, Kapitanyan R, Alter SM, Jeges J, Lui J, et al. Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med. 2010; 28: 296-303.
26. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction. 2001; 100: 1823-31.
27. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health Bull N Y Acad Med. 2005; 82(02): 303-11.
28. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg S. Prescribing naloxone to actively injection heroin users: a program to reduce heroin overdose death. J Addict Dis. 2006; 25(3): 89-96.
29. Piper TM, Rudenstine S, Stancliff S, et al. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduction J. 2007; 4(3): 1-8.
30. Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med. 2007; 49(2): 172-7.
31. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and distribution programs in the US. Addiction. 2008: 1-11.
32. Strang J, Manning V, Mayet S, et al. Family carers and the prevention of heroin overdose deaths: unmet training need and overlooked intervention opportunity of resuscitation training and supply of naloxone. Drug Educ Prev Policy. 2008; 15(2): 211-8.
33. Sherman SG, Gann DS, Tobin KE, et al. "The life they same may be mine": diffusion of overdose prevention information from a city sponsored programme. Int J Drug Policy. 2009; 20: 137-42.
34. Advisory Council on Misuse of Drugs. Consideration of naloxone. May 2012. http://www. homeoffice. gov. uk/publications/agencies-public-bodies/acmd1/consideration-of-naloxone?view=Binary. Accessed June 1, 2012.
35. Constantino HR, Illum L, Brandt G, et al. Int J Pharm. 2007; 337: 1-24.
36. Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration. Pharmacol Ther. 2012; 134: 366-79.
37. Illum L. Nasal clearance in health and disease. J Aerosol Med. 2006; 19: 92-9.
38. van den Donk HJ, van den Huervel AG, Zuidema J, Merkus FW. The effects of nasal drops and their additives on human nasal mucociliary clearance. Rhinology. 1982; 20: 127-37.
39. Merkus P, Ebbens FA, Muller B, Fokkens WJ. Influence of anatomy and head position on intranasal drug deposition. Eur Arch Otorhinolaryngol. 2006; 263: 827-32.
40. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11: 1-18.
41. Illum L. Is nose to brain transport of drugs a reality? JPP. 2004; 56: 3-17.
42. Merkus F, van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs. 2007; 8: 133-44.
43. Davis GA, Rudy AC, Archer SA, Wermeling DP, McNamara PJ. Effect of fluticasone propionate nasal spray on bioavailability of hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy. 2004; 24: 26-32.
44. Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ. Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. Clin Drug Invest. 2004; 24: 1-7.
45. Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al. A review of the clinical pharmacokinetics of opioids, benzodiazepines and antimigraine drugs delivered intranasally. Clin Ther. 2009; 31: 2954-87.
46. Holsti M, Sill B, Firth S, et al. Prehospital intranasal midazolam for the treatment of pediatric seizures. Pediatr Emerg Care. 2007; 23: 148-53.
47. Wermeling DP, Clinch T, Rudy AC, et al. A multicenter, open label, exploratory dose-ranging trial of hydromorphone for managing acute pain from trauma. J Pain. 2010; 11(1): 24-31.
48. Rudy AC, Coda BA, Wermeling DP. A multiple dose phase 1 study of intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2004; 99: 1379-86.
49. Davis GA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. Am J Health Syst Pharm. 2004; 61: 261-6.
50. Illum L. Nasal drug delivery-recent developments and future prospects. J Cont Release. 2012; 161(2): 254-63.
51. Goodman and Gilman's, The Pharmacologic Basis of Therapeutics. 10th edition. New York, NY: McGraw Hill. p. 569-620.
52. Hussain A, Kimura R, Huang C-H, Kashihara T. Nasal absorption of naloxone and buprenorphine in rats. Int J Pharm. 1984; 21: 233-7.
53. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008; 30: 490-6.
54. Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011; 106: 1460-73.
55. Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone for detection of opiate dependence. J Psychiatr Res. 1992; 26: 39-43.
56. Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict. 1994; 29: 819-27.
57. Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998; 5: 293-9.
58. Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005; 29: 265-71.
59. Barton ED, Ramos J, Colwell C, Benson J, Baily J, Dunn W. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care. 2002; 6: 54-8.
60. Buajordet I, Næss A-C, Jacobsen D, Brørs O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004; 11: 19-23.
61. Osterwalder JJ. Naloxone-for intoxications with intravenous heroin and heroin mixtures-harmless of hazardous? A prospective clinical study. Clin Toxicol. 1996; 34: 409-16.
62. Kim D, Irwin KS, Khoshknod K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose and mortality. Am J Public Health. 2009; 99: 402-7.
63. Project Lazarus. Accessed June 1, 2012. www. projectlazarus. org.
64. Leavitt SB. Intranasal naloxone for at-home opioid rescue. Pract Pain Manag. 2010 October 2010.